15 insiders reported 106 Form 4 transactions for CATALYST PHARMACEUTICALS, INC. (CPRX) over the past 18 months (most recent 2026-06-05). Recent activity: Andrews William T. (Chief Medical Officer) Buy 3,052 shares, Andrews William T. (Chief Medical Officer) Sell 743 shares, Russo Gregg (Chief HR Officer) Buy 687 shares, Russo Gregg (Chief HR Officer) Sell 211 shares, Kalb Michael Wayne (Executive Vice President & CFO) Buy 7,139 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-05 | Andrews William T. | Chief Medical Officer | Buy | 3,052 | $0 |
| 2026-06-05 | Andrews William T. | Chief Medical Officer | Sell | 743 | $0 |
| 2026-02-19 | Russo Gregg | Chief HR Officer | Buy | 687 | $0 |
| 2026-02-19 | Russo Gregg | Chief HR Officer | Sell | 211 | $0 |
| 2026-01-06 | Kalb Michael Wayne | Executive Vice President & CFO | Buy | 7,139 | $0 |
| 2026-01-06 | Kalb Michael Wayne | Executive Vice President & CFO | Sell | 2,080 | $0 |
| 2026-01-06 | Daly Richard J | President and CEO | Buy | 42,105 | $0 |
| 2026-01-06 | Daly Richard J | President and CEO | Sell | 10,577 | $0 |
| 2025-12-30 | Del Carmen Jeffrey | Chief Commercial Officer | Buy | 8,667 | $0 |
| 2025-12-30 | Harper Molly | Director | Buy | 1,334 | $0 |
| 2025-12-30 | Daly Richard J | President and CEO | Buy | 1,334 | $0 |
| 2025-12-30 | Daly Richard J | President and CEO | Sell | 524 | $0 |
| 2025-12-30 | Tierney David S | Director | Buy | 1,334 | $0 |
| 2025-12-30 | Del Carmen Jeffrey | Chief Commercial Officer | Sell | 3,839 | $0 |
| 2025-12-30 | Sundaram Preethi | Chief Strategy Officer | Buy | 6,667 | $0 |
| 2025-12-30 | Sundaram Preethi | Chief Strategy Officer | Sell | 2,369 | $0 |
| 2025-12-30 | MCENANY PATRICK J | Director | Buy | 26,334 | $0 |
| 2025-12-30 | MCENANY PATRICK J | Director | Sell | 6,786 | $0 |
| 2025-12-30 | Elsbernd Brian | Chief Compliance/Legal Officer | Buy | 6,667 | $0 |
| 2025-12-30 | Elsbernd Brian | Chief Compliance/Legal Officer | Sell | 2,623 | $0 |
| 2025-12-30 | DENKHAUS DONALD A | Director | Buy | 1,334 | $0 |
| 2025-12-30 | Miller Steve | Chief Op. & Scientific Officer | Buy | 14,000 | $0 |
| 2025-12-16 | Harper Molly | Director | Buy | 20,000 | $115,600 |
| 2025-12-16 | Harper Molly | Director | Sell | 15,527 | $360,226 |
| 2025-12-16 | Harper Molly | Director | Sell | 4,473 | $106,144 |
Source: SEC Form 4 filings · as of 2026-06-05